Key Takeaways Semaglutide suppresses appetite by mimicking the GLP-1 hormone, which activates receptors in the brain
Gastrointestinal Very common (10% or more): Nausea (up to 18%), diarrhea (up to 17%) Common (1% to 10%): Vomiting, constipation, dyspepsia, abdominal pain, eructation, flatulence, gastroesophageal reflux disease, abdominal distension Uncommon (0.1% to 1%): Cholelithiasis, acute pancreatitis, increased serum pancreatic amylase levels, increased serum lipase levels, acute gallbladder disease (including cholelithiasis, biliary colic and cholecystectomy) Postmarketing reports : Ileus In pooled placebo-controlled trials, treatment with this drug resulted in mean increases from baseline in serum pancreatic amylase levels of up to 38% and serum lipase levels of up to 42%
Pinch the skin, insert at 45 degrees, push the plunger slowly, remove, and dispose of the needle in your sharps container
Less body fat means less natural insulation
Ivim Health GLP-1 Medication Options FAQ Spotlight: Is a specific medication or brand guaranteed on Ivim Health